The cytochrome P450 superfamily of enzymes play a central part in the metabolism of carcinogens and anti-cancer drugs. The expression, cellular localisation, and distribution of different forms of P450 and the functionally associated enzymes epoxide hydrolase and glutathione S-transferases have been investigated in oesophageal cancer and non-neoplastic oesophageal tissue using immunohistochemistry. Expression of the different enzymes was confined to epithelial cells in both non-neoplastic samples and tumour samples except that CYP3A was also identified in mast cells and glutathione Stransferase pi was present in chronic inflammatory cells. CYPlA was present in a small percentage of non-neoplastic samples but both CYP2C and CYP3A were absent. Epoxide hydrolase was present in half of the nonneoplastic samples and the different classes of glutathione S-transferase were present in a low number of samples. In carcinomas CYP1A, CYP3A, epoxide hydrolase, and glutathione S-transferase pi were expressed in at least 60% of samples. The expression of glutathione S-transferases alpha and mu were significantly less in adenocarcinoma compared with squamous carcinoma. (Gut 1994; 35: 599-603) metabolism of compounds initially metabolised by P450. Epoxide hydrolases participating in xenobiotic metabolism comprise mainly one microsomal and one cytosolic form, which convert potentially toxic epoxides to less reactive dihydrodiols, although subsequent reoxidation can lead to the formation of diol-epoxide derivatives, which are often more toxic than the parent compounds.5 The glutathione S-transferases, like the cytochromes P450, are a complex gene family of enzymes, which catalyse the conjugation of reduced glutathione with a variety of electrophilic compounds generally resulting in less toxic, more hydrophilic compounds, which can be more easily excreted.6'5 Like the cytochromes P450 the liver is the main organ in which the glutathione S-transferases are expressed and specific classes of glutathione S-transferases are present in many extrahepatic tissues.
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There is little information regarding the presence, distribution, and localisation of different xenobiotic metabolising enzymes in either normal oesophagus or oesophageal tumours and in this study we (Figs  1-3 ), although in a few cases nuclear staining for the different classes of glutathione S-transferases was also seen. The immunoreactivity for each enzyme had a uniform distribution throughout each tumour. In addition, mast cells in normal and carcinoma samples consistently showed strong positive staining for CYP3A while glutathione S-transferase pi immunoreactivity was also identified in chronic inflammatory cells.
Discussion
We have investigated specific sub-families the expression of three of cytochrome P450 (CYP1A, CYP2C, CYP3A) and the functionally associated enzymes epoxide hydrolase and glutathione S-transferase in oesophageal cancer and non-neoplastic oesophagus. The presence in the diet of carcinogens or pro-carcinogens, which can be metabolically activated is an important factor in the development of oesophageal cancer2 and these compounds are generally metabolised by the xenobiotic metabolising forms of cytochrome P450. The outcome of metabolism in terms of activation (toxicity) or deactivation (detoxification) will depend on the cellular localisation, comparative amount, and activity of the different xenobiotic metabolising enzymes present in a particular tissue. In nonneoplastic oesophagus there was only a low frequency of expression of the enzymes studied and in particular there was no expression of CYP3A. Samples of non-neoplastic oesophagus were obtained from the proximal resection margins of oesophagectomy specimens that contained tumour. Although these specimens displayed no histological abnormality they may not be functionally strictly normal, as they had been obtained from specimens that contained tumour. Ethically, however, it is not possible to obtain entirely normal oesophagus. A low level of P450 associated mono-oxygenase activity towards Nnitrosomethyl-n-amylamine has been identified in microsomes prepared from non-neoplastic human oesophageal mucosa although the particular form or forms of P450 contributing to this activity were not identified.22
Within the human alimentary tract CYP3A is present in a high concentration in the small intestine'8 23 but either absent or present at a low concentration from colon2' and it is suggested that a high concentration of CYP3A in the small intestine protects the small intestine from the development of cancer. 24 Conversely, the absence of CYP3A from other sites in the alimentary tract may contribute to the frequent development of malignancy. The failure to detect immunoreactive CYP3A in nonneoplastic oesophagus may support this hypothesis.
There have been no extensive investigations of drug metabolising enzymes in oesophageal neoplasia. The only xenobiotic metabolising enzyme that has been studied in oesophageal malignancy is the pi class of glutathione Stransferase.2127 Both glutathione S-transferase pi mRNA and protein are present in low amounts in non-neoplastic oesophagus but at an increased level in a high proportion of oesophageal squamous carcinomas.
The two different histological groups of oesophageal tumours, namely squamous carcinoma and adenocarcinoma, generally showed a similar pattern of expression of the different enzymes studied with the exception that the glutathione S-transferases alpha and mu were expressed significantly less in adenocarcinoma than squamous carcinoma. The differential expression of these forms of glutathione S-transferase may provide an opportunity clinically for the improved selection of anti-cancer drugs based on knowledge of their metabolism by these forms of glutathione S-transferases.
Almost all the tumours displayed positive epoxide hydrolase immunoreactivity and we have previously identified epoxide hydrolase immunoreactivity in a variety of different malignant tumours including hepatoma,20 colon cancer, and breast cancer,28 which suggests that epoxide hydrolase expression may be a common molecular event in malignancy.
In conclusion, we have found non-neoplastic oesophageal epithelium to be characterised by a low frequency of expression of different xenobiotic metabolising enzymes, with CYP2C and CYP3A being undetectable. In oesophageal cancer the phenotypic expression of the different enzymes was complex with the presence in at least 60% of all tumours of CYPlA and CYP3A, epoxide hydrolase and glutathione S-transferase pi. The frequent expression of the different xenobiotic metabolising enzymes in oesophageal cancer may contribute to the anti-cancer drug resistance that is characteristic of oesophageal cancer.
